Shantou Institute of Ultrasonic Instrument
301602
Hubei Sinophorus Electronic Materials
688545
Pansoft
300996
4
Jiayu Holding
300117
5
Wuxi Taclink Optoelectronics Technology
688205
US Stock MarketDetailed Quotes
SLRN Acelyrin
- 1.970
- -0.020-1.01%
Trading Jan 22 12:32 ET
197.64MMarket Cap-0.74P/E (TTM)
2.050High1.935Low340.96KVolume1.990Open1.990Pre Close670.58KTurnover0.57%Turnover RatioLossP/E (Static)100.33MShares8.88552wk High0.37P/B118.64MFloat Cap1.91052wk Low--Dividend TTM60.22MShs Float29.880Historical High--Div YieldTTM5.78%Amplitude1.910Historical Low1.966Avg Price1Lot Size
Trending Stocks
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Stocks & Industries to Watch Under Trump's Second Presidency
Key takeaways Tech stocks underwent substantial growth due to tax cuts and reduced corporate regulations in Trump's first term along with defense and aerospace
Discussing
December CPI comes in as expected, is that enough?
U.S. December CPI rose 2.9% year-on-year, aligning with expectations but marking a three-month inflation increase trend. The market reacted
In One Chart
Jan 15 22:05
Here's the Breakdown for December CPI, in One Chart
Acelyrin Stock Forum
ACELYRIN Inc - Lonigutamab Shows Potential Efficacy and Favorable Safety Profile in Ted
ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab
Thursday, 2nd January at 8:00 pm
LOS ANGELES, Jan. 02, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a virtual investor event on Monday, January 6, 2025 at 4:30 PM ET to pro...
ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis
ACELYRIN (Nasdaq: SLRN) announced that its Phase 2b/3 trial of izokibep in non-infectious, non-anterior uveitis failed to meet its primary endpoint of showing statistically significant improvement in time to treatment failure versus placebo at 24 weeks. Secondary endpoints also did not achieve statistical significance.
Following these results and previous guidance, AC...
No comment yet